Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigabatrin in Refractory Autoimmune Encephalitis
NCT03003143Withdrawn
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2016
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vigabatrin in Autoimmune Encephalitis (AE), sponsored by Seoul National University Hospital. Primary endpoint: Seizure frequency reduction at 3 months. Planned start Nov 2016; status: withdrawn.
02
Drugs
vigabatrin
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT03003143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03003143.